Story Highlight
– MHRA approves UK’s first GLP-1 receptor agonist tablet.
– Tablet for obesity to be prescribed with lifestyle changes.
– Eligibility requires BMI of 30 or health-related conditions.
– Not available through NHS; private prescription needed.
– Common side effects include gastrointestinal disorders.
Full Story
Health officials have approved a tablet variant of a well-known weight loss injection, marking a significant development in obesity treatment within the UK. The decision, announced on Thursday by the Medicines and Healthcare products Regulatory Agency (MHRA), introduces the first oral GLP-1 receptor agonist for managing weight and obesity in the country. The semaglutide tablet, branded as Wegovy, is now available to be prescribed for adults facing obesity, in conjunction with a calorie-restricted diet and increased physical exercise.
However, patients must meet certain criteria to qualify for this medication and can only access it through specific channels. To be prescribed the Wegovy tablet, individuals must have a minimum Body Mass Index (BMI) of 30 or a BMI between 27 and 30 with at least one obesity-related health condition.
The recommended initial dosage for the semaglutide tablet is 1.5 mg, taken daily. This can then progress to dosages of 4 mg, 9 mg, and eventually 25 mg, with each dosage to be maintained for a minimum of one month. For current users of the semaglutide injection, which is administered weekly at a dose of 2.4 mg, a direct switch to the oral formulation of 25 mg daily is possible, according to reports.
The function of semaglutide lies in its role as a GLP-1 receptor agonist. It mimics the natural hormone glucagon-like peptide (GLP-1) released post-meal, influencing brain regions responsible for appetite regulation. This mechanism promotes a sense of fullness, curbs hunger, and decreases cravings, thereby facilitating reduced food intake and supporting weight loss, provided it is coupled with appropriate dietary and lifestyle adjustments. The MHRA has underscored the importance of adhering to instructions outlined in the Patient Information Leaflet for optimal results. For effective absorption, the tablet must be taken whole on an empty stomach, ideally after an overnight fast of at least eight hours, alongside a small amount of water. Following ingestion, individuals should refrain from eating or drinking for a minimum of 30 minutes to ensure proper absorption.
In the announcement regarding the drug’s approval, Julian Beach, Executive Director of Healthcare Quality and Access at the MHRA, clarified the nature of access to the medication: “As with all GLP-1 receptor agonists, this is a prescription-only medication.” Importantly, while the tablet has been sanctioned for use, it is not presently available through the National Health Service (NHS). Decisions about its introduction into NHS provision will follow the standard procedures, which include assessment by the National Institute for Health and Care Excellence (NICE). Consequently, individuals seeking treatment will need to turn to private healthcare services, incurring additional costs.
In terms of potential side effects, the MHRA has mentioned that gastrointestinal issues are the most frequently reported, encompassing nausea, diarrhoea, constipation, and vomiting. The agency has committed to ongoing surveillance of the drug’s safety and efficacy, advising anyone experiencing adverse effects to consult their healthcare provider and to report these incidents via the MHRA Yellow Card scheme, accessible through an official website or mobile application.
Despite the introduction of the oral version, there are compelling reasons why some individuals may continue to favour injection treatments over tablets. Suhail Jamil, Superintendent Pharmacist at Ashcroft Pharmacy, remarked, “Many are assuming that the tablet will be the most convenient option, but that won’t necessarily be the case.”
Jamil also pointed out that the Wegovy pill is anticipated to attract interest, particularly among individuals averse to needles. However, the injectable formulation may be viewed as a less burdensome option, as it requires administration only once a week, as opposed to a daily dosage for the tablet. The planning required to consistently take the tablet may pose challenges, particularly for individuals whose lifestyles involve shift work or those prone to forgetfulness. “The tablet will likely encourage more people to start weight loss treatment, rather than hugely encouraging those already on the jabs to make the switch,” he added. Preferences will ultimately depend on personal lifestyle and individual circumstances rather than simply the choice between a pill and an injection.
Cost remains a pertinent topic, yet Jamil has noted that no official pricing has been established for the Wegovy tablets in the UK. In the United States, the price ranges from $149 to $299 (£111 to £222) monthly, with certain insurance plans potentially reducing costs to around $25 (£18). Generally, the oral formulation is touted as being less expensive than its injectable counterpart and other medications in the GLP-1 category.
As for availability timelines, Jamil stated that specifics on the UK release of Wegovy tablets are yet to be confirmed. Following its approval by the FDA in December 2025, the product became accessible in US pharmacies shortly thereafter. It is crucial for individuals considering weight loss solutions to refrain from procuring the Wegovy tablet from any unofficial sources until it receives full regulatory approval in the UK. Consultation with healthcare professionals is strongly advised for anyone considering this treatment avenue.
Our Thoughts
The approval of the semaglutide tablet raises several health and safety considerations under UK legislation. To prevent potential misuse or adverse effects, robust patient education about the proper intake and guidelines outlined in the Patient Information Leaflet is crucial. A comprehensive implementation of the Health and Safety at Work Act 1974 requires that information, instruction, and training be adequately provided to patients and healthcare providers.
Strict adherence to the Misuse of Drugs Act 1971 and appropriate prescription protocols is necessary to prevent the medication from being improperly accessed, considering its classification as a prescription-only drug. Additionally, the MHRA must ensure ongoing monitoring aligns with the requirements of the Medicines Act 1968 to capture and evaluate side effects effectively.
By enhancing communication about the importance of the medication’s uptake criteria, potential side effects, and proper usage, the risk of adverse effects or patient non-compliance could be minimized. Future guidelines could also explore better support systems for individuals managing complex dosing schedules, particularly those in varying work routines, to reduce the risk of missed doses, enhancing safety and treatment efficacy.
